期刊文献+

Ability of luteinizing hormone releasing hormone-Pseudomonas aeruginosa exotoxin 40 binding to LHRH receptor on human liver cancer cells 被引量:8

Ability of luteinizing hormone releasing hormone-Pseudomonas aeruginosa exotoxin 40 binding to LHRH receptor on human liver cancer cells
下载PDF
导出
摘要 AIM: TO explore the ability of recombinant toxin luteinizinghormone releasing hormone-Pseudomonas aeruginosaexotoxin 40 (LHRH-PE40) and LHRH binding to LHRH receptor(LHRHR) on the membrane surface of human liver cancerHEPG cells.METHODS: LHRH was labeled by using 12sI with enzymaticreaction. The affinity and receptor volume of LHP, H-PE40and LHRH binding to LHRHR on the membrane surface ofhuman liver cancer cells were measured with radioligandreceptor assay.RESULTS: The specific activity of LHRH labeled with 12sIwas 2.7x 104 kBq/l^L, and its radiochemical purity reachedto 99.2-99.7%. The binding of 12sI to LHRH was maximalfor 240 min in the warm cultivation, and this binding wasstabilized. The inhibiting rates of ~2SI-LHRH and LHRH onthe proliferation of human liver cancer HEPG cells werenot significantly different. On the basis of the saturationcurve of ~2SI-LHRH binding to the membrane LHRHR of HEPGcells, ~2SI-LHRH of lx10s cpm was selected for radioligandreceptor assay. The affinity constants (Kd) of LHRH-PE40and LHRH binding to the membrane LHRHR of HEPG cellswere 0.43~0.12 nmol/L and 4.86~ 1.47 nmol/L, respectively,and their receptor volumes were 0.37~0.15 l^mol/g and0.42=I=0.13 l^mol/g, respectively. The binding of LHRH-PE40to the membrane protein of normal liver cells was notobserved.CONCLUSION: The recombinant toxin LHRH-PE40 binding tothe membrane surface of LHRHR of human liver cancer HEPGcells was very strong, while the specific binding of it to normalliver cells was not observed. The results provide an importantexperimental basis for the clinical application of LHRH-PE. AIM:To explore the ability of recombinant toxin luteinizing hormone releasing hormone-Pseudomonas aeruginosa exotoxin 40(LHRH-PE40)and LHRH binding to LHRH receptor (LHRHR)on the membrane surface of human liver cancer HEPG cells. METHODS:LHRH was labeled by using ^(125)I with enzymatic reaction.The affinity and receptor volume of LHRH-PE40 and LHRH binding to LHRHR on the membrane surface of human liver cancer cells were measured with radioligand receptor assay. RESULTS:The specific activity of LHRH labeled with ^(125)I was 2.7×10~4 kBq/μL,and its radiochemical purity reached to 99.2-99.7%.The binding of ^(125)I to LHRH was maximal for 240 min in the warm cultivation,and this binding was stabilized.The inhibiting rates of ^(125)I-LHRH and LHRH on the proliferation of human liver cancer HEPG cells were not significantly different.On the basis of the saturation curve of ^(125)I-LHRH binding to the membrane LHRHR of HEPG cells,^(125)I-LHRH of 1×10~5 cpm was selected for radioligand receptor assay.The affinity constants(Kd)of LHRH-PE40 and LHRH binding to the membrane LHRHR of HEPG cells were 0.43±0.12 nmol/L and 4.86±1.47 nmol/L,respectively, and their receptor volumes were 0.37±0.15 μmol/g and 0.42±0.13 μmol/g,respectively.The binding of LHRH-PE40 to the membrane protein of normal liver cells was not observed. CONCLUSION:The recombinant toxin LHRH-PE40 binding to the membrane surface of LHRHR of human liver cancer HEPG cells was very strong,while the specific binding of it to normal liver cells was not observed.The results provide an important experimental basis for the clinical application of LHRH-PE.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2004年第19期2870-2873,共4页 世界胃肠病学杂志(英文版)
基金 Supported by the Key Programs of National Science and Technology,No.96-901-05-101
  • 相关文献

参考文献27

  • 1Panchal RG. Novel therapeutic strategies to selectively kill cancer cells. Biochem Pharmacol 1998; 55:247-252.
  • 2Reiter Y, Pastan I. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis.Trends Biotechnol 1998; 16:513-520.
  • 3Perentesis JP, Gunther R, Waurzyniak B, Yanishevski Y, Myers DE, Ek O, Messinger Y, Shao Y, Chelstrom LM, Schneider E,Evans WE, Uckun FM. In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colonystimulating factor receptor. Clin Cancer Res 1997; 3(12 Pt 1):2217-2227.
  • 4Saleh MN, LeMaistre CF, Kuzel TM, Foss F, Platanias LC,Schwartz G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J,Sams MW, Nichols JC. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 1998;39:63-73.
  • 5Kreitman RJ, Wilson WH, Robbins D, Margulies I, StetlerStevenson M, Waldmann TA, Pastan I. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 1999;94:3340-3348.
  • 6Haggerty HG, Warner WA, Comereski CR, Peden WM, Mezza LE, Damle BD, Siegall CB, Davidson TJ. BR96 sFv-PE40 immunotoxin: nonclinical safety assessment. Toxicol Pathol 1999; 27:87-94.
  • 7Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH,Heald PW, Bacha P, Nichols J, Liepa A. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK(R)). Clin Lymphoma 2002; 2:222-228.
  • 8Zhao G, Gong SL, Yue Y, Zhu P. Distribution of human LHRH receptors in normal and carcinomatous tissues outside pituitary. Jilin Daxue Xuebao 2002; 28:445-447.
  • 9Zhao G, Gong SL, Zhu P. Binding ability of LHRH-PE40 to LHRH receptors on the surface of cancer cell line. Jilin Daxue Xuebao 2003; 29:5-8.
  • 10Dharap SS, Qiu B, Williams GC, Sinko P, Stein S, Minko T.Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J Control Release 2003; 91:61-73.

同被引文献22

引证文献8

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部